50
Participants
Start Date
October 31, 2007
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
Bevacizumab
10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
Everolimus
10 mg Everolimus(RAD001) daily by mouth, days 1-28
Duke University Medical Center, Durham
Collaborators (2)
Novartis Pharmaceuticals
INDUSTRY
Genentech, Inc.
INDUSTRY
Herbert Hurwitz
OTHER